POLARGO
Phase 3 Completed
270 enrolled 36 charts
Olaparib and High-Dose Chemotherapy in Treating Patients With Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant
Phase 1 Completed
50 enrolled
Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase 1/2 Completed
3 enrolled 10 charts
Study of Brentuximab Vedotin in Patients With R/R PTCL Treated With Gemcitabine
Phase 2 Completed
71 enrolled
TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers
Phase 1 Completed
56 enrolled 19 charts
Gemcitabine Hydrochloride, Clofarabine, and Busulfan Before Donor Stem Cell Transplant in Treating Patients With Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
64 enrolled 13 charts
NIVEAU
Phase 2/3 Completed
348 enrolled
BURGUND
Phase 2 Completed
115 enrolled
A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Phase 1/2 Completed
169 enrolled
Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT
Phase 2 Completed
64 enrolled 17 charts
A Study of Surufatinib in Combination With Gemcitabine in Pediatric, Adolescent, and Young Adult Patients With Recurrent or Refractory Solid Tumors
Phase 1/2 Completed
13 enrolled 17 charts
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors
Phase 1 Completed
68 enrolled
KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Phase 2 Completed
71 enrolled 15 charts
A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma
Phase 1 Completed
23 enrolled 17 charts
Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
33 enrolled 14 charts
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Phase 2 Completed
25 enrolled 10 charts
Chidamide + R-GemOx Regimen as Salvage Treatment for Transplant-ineligible Patients With Relapsed/Refractory DLBCL
Phase 2 Completed
54 enrolled
Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma
Phase 2 Completed
29 enrolled
Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma
Phase 1 Completed
21 enrolled
Copanlisib and Gemcitabine in Relapsed/Refractory PTCL
Phase 1/2 Completed
28 enrolled
SELINDA
Phase 1 Completed
39 enrolled
PIX-R
Phase 3 Completed
312 enrolled 16 charts
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 1/2 Completed
26 enrolled 13 charts
Brentuximab Vedotin and Gemcitabine Hydrochloride in Treating Younger Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1/2 Completed
46 enrolled 18 charts
GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell Lymphoma
Phase NA Completed
52 enrolled
BeGeRN
Phase 1/2 Completed
30 enrolled
Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Phase 1 Completed
24 enrolled
Chemotherapy for Participants With Lymphoma
Phase 2 Completed
68 enrolled 20 charts
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
Phase 1 Completed
19 enrolled
Combination Chemotherapy in Hodgkin's Disease or Non-Hodgkin's Lymphoma Not Responding to Previous Treatment
Phase 2 Completed
77 enrolled
A Study of GDC-0575 Alone and in Combination With Gemcitabine in Participants With Refractory Solid Tumors or Lymphoma
Phase 1 Completed
104 enrolled
BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)
Phase 3 Completed
140 enrolled 15 charts
Aza-SAHA-GBM With AutoSCT for Refractory Lymphoma
Phase 1/2 Completed
61 enrolled 10 charts
High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease
Phase 2 Completed
81 enrolled 8 charts
Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Phase 2/3 Completed
111 enrolled 20 charts
Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Completed
25 enrolled
FIL_GEMRO
Phase 2 Completed
20 enrolled 11 charts
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Phase 3 Completed
271 enrolled 25 charts
RGemOx
Phase 2 Completed
82 enrolled
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Phase 2 Completed
146 enrolled 12 charts
Gemcitabine in Treating Patients With Recurrent Chronic Lymphocytic Leukemia
Phase 2 Completed
22 enrolled
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
Phase 1 Completed
172 enrolled 13 charts
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 1/2 Completed
91 enrolled
INPAKT
Phase 1 Completed
52 enrolled
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase 2 Completed
104 enrolled
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Phase 1 Completed
145 enrolled
Phase Ib/II Study of the Efficacy and Safety of the R-CMC544/R-GEMOX Combination in Diffuse Lage B-cell Lymphoma at First or Second Relapse
Phase 1/2 Completed
11 enrolled
Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 2 Completed
18 enrolled 8 charts
Rituximab in Combination With Outpatient Therapy for CD20+ Lymphoma
Phase 2 Completed
12 enrolled
Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma
Phase 2 Completed
40 enrolled